Search results
Your search for Ovelle returned no results
Showing 31 to 45 of 50 results for overly
Showing 31 to 45 of 50 results for overly
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Evidence-based recommendations on quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care
Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)
Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults.